Dynamic Technology Lab Private Ltd Purchases New Position in Schrödinger, Inc. (NASDAQ:SDGR)

Dynamic Technology Lab Private Ltd acquired a new position in shares of Schrödinger, Inc. (NASDAQ:SDGR) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,067 shares of the company’s stock, valued at approximately $298,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SDGR. Nisa Investment Advisors LLC grew its holdings in shares of Schrödinger by 145.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,413 shares of the company’s stock worth $27,000 after purchasing an additional 837 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Schrödinger by 49.5% during the 2nd quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock valued at $41,000 after purchasing an additional 703 shares during the last quarter. KBC Group NV boosted its position in Schrödinger by 45.4% in the third quarter. KBC Group NV now owns 2,508 shares of the company’s stock valued at $47,000 after buying an additional 783 shares in the last quarter. nVerses Capital LLC bought a new stake in Schrödinger during the second quarter worth about $66,000. Finally, Quest Partners LLC increased its holdings in shares of Schrödinger by 1,005.6% during the second quarter. Quest Partners LLC now owns 4,555 shares of the company’s stock worth $88,000 after buying an additional 4,143 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Schrödinger Stock Performance

Shares of SDGR opened at $22.57 on Monday. The business’s fifty day moving average price is $18.84 and its two-hundred day moving average price is $20.16. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -9.65 and a beta of 1.50. Schrödinger, Inc. has a 52 week low of $16.67 and a 52 week high of $38.00.

Schrödinger (NASDAQ:SDGR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.12). The firm had revenue of $35.30 million during the quarter, compared to the consensus estimate of $41.25 million. Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. Schrödinger’s revenue was down 17.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.86) EPS. As a group, research analysts forecast that Schrödinger, Inc. will post -2.29 EPS for the current year.

Insider Transactions at Schrödinger

In other news, insider Margaret Dugan sold 1,531 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $17.78, for a total value of $27,221.18. Following the transaction, the insider now directly owns 13,469 shares in the company, valued at $239,478.82. This trade represents a 10.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Morgan Stanley reduced their target price on Schrödinger from $43.00 to $30.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 21st. BMO Capital Markets boosted their price objective on Schrödinger from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.90.

Schrödinger Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.